A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size D, in the range of 3 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

Proposed is a pharmaceutical composition for oral administration, the composition including an ionic bond complex composed of teriparatide, deoxycholic acid, Nα-deoxycholyl-L-lysyl-methylester (DCK), and di-alpha-tocopherol polyethylene glycol 1000 succinate, and a method for preparing the same is also proposed. The oral pharmaceutical composition is useful for the treatment of osteoporosis because the pharmaceutical composition can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance.

Proposed is a pharmaceutical composition for oral administration, the composition including an ionic bond complex composed of teriparatide, deoxycholic acid, Nα-deoxycholyl-L-lysyl-methylester (DCK), and di-alpha-tocopherol polyethylene glycol 1000 succinate, and a method for preparing the same is also proposed. The oral pharmaceutical composition is useful for the treatment of osteoporosis because the pharmaceutical composition can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emusion is greater than about 9.

Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emusion is greater than about 9.

Provided is an aqueous solution as a continuous phase, the aqueous solution comprising: a first plurality of polymers; and a first plurality of active ingredients; and one or more nanoparticles, as a dispersed phase, the one or more nanoparticles comprising: a first plurality of carrier solvents; and a second plurality of active ingredients, wherein: the second plurality of active ingredients have at least 5 times higher absorption in-vivo when located inside the one or more nanoparticles compared to when administered in an aqueous solution.